Zou Yan-Feng, Wang Yu, Liu Ping, Feng Xiao-Liang, Wang Bin-Yan, Zang Tong-Hua, Yu Xin, Wei Jing, Liu Zhong-Chun, Liu Ying, Tao Ming, Li Hui-Chun, Li Ke-Qing, Hu Jian, Li Ming, Zhang Ke-Rang, Ye Dong-Qing, Xu Xi-Ping
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.
Hum Psychopharmacol. 2010 Mar;25(2):145-52. doi: 10.1002/hup.1099.
To explore the association of brain-derived neurotrophic-factor (BDNF) Val66Met polymorphism with both baseline health related quality of life (HRQOL) scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.
Patients with major depressive disorder (MDD) took fluoxetine (20 mg/day) for 6 weeks. The HRQOL was measured with the Medical Outcomes Study Short Form-36 (SF-36) at baseline and at 6th week. Patients were genotyped for Val66Met polymorphism of BDNF gene.
There was a significant association between social function (SF) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had better SF (compared with Val/Val P = 0.004; compared with Val/Met P = 0.005). A significant association was found between improvement in SF and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in SF (compared with Val/Val P = 0.010; compared with Val/Met P = 0.001). Similar association was found between improvement in mental component summary (MCS) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in MCS (compared with Val/Val P = 0.066; compared with Val/Met P = 0.006).
These results indicate that there may be association between BDNF Val66Met polymorphism and both baseline HRQOL (SF) scores and improvement in HRQOL (SF, MCS) scores in Chinese major depressive patients treated with fluoxetine.
探讨脑源性神经营养因子（BDNF）Val66Met多态性与接受氟西汀治疗的中国重度抑郁症患者的基线健康相关生活质量（HRQOL）评分以及HRQOL评分改善情况之间的关联。
重度抑郁症（MDD）患者服用氟西汀（20毫克/天），持续6周。在基线和第6周时，使用医学结局研究简表36（SF-36）测量HRQOL。对患者进行BDNF基因Val66Met多态性基因分型。
社会功能（SF）与BDNF Val66Met多态性之间存在显著关联，Met/Met基因型患者的SF更好（与Val/Val相比，P = 0.004；与Val/Met相比，P = 0.005）。SF改善与BDNF Val66Met多态性之间存在显著关联，Met/Met基因型患者的SF改善较差（与Val/Val相比，P = 0.010；与Val/Met相比，P = 0.001）。在心理成分总结（MCS）改善与BDNF Val66Met多态性之间发现了类似的关联，Met/Met基因型患者的MCS改善较差（与Val/Val相比，P = 0.066；与Val/Met相比，P = 0.006）。
这些结果表明，BDNF Val66Met多态性与接受氟西汀治疗的中国重度抑郁症患者的基线HRQOL（SF）评分以及HRQOL（SF、MCS）评分改善之间可能存在关联。
